ArticleJournal of the American Society of Nephrology : JASN2010
Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis.
Article in Journal of the American Society of Nephrology : JASN, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 50 citations in OpenAlex.
- Trial
- Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2016Trial
- Deprivation and chronic kidney disease-a review of the evidence.Clinical kidney journal · 2023Review
- Metabolite profiling of CKD progression in the chronic renal insufficiency cohort study.JCI insight · 2022Article
- Longitudinal Follow-Up and Outcomes for Chinese Patients with Stage 1-4 Chronic Kidney Disease.Kidney diseases (Basel, Switzerland) · 2022Article
- Exploring psychosocial stressors as contributors to racial disparity in end-stage renal disease.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2021Article
- Outcomes of patients with end-stage kidney disease hospitalized with COVID-19.Kidney international · 2020Observational
- Markers and risk factors for chronic kidney disease in sub-Saharan Africans: baseline levels and 12-month trajectories in newly referred patients in Cameroon.BMC nephrology · 2020Article
- Kidney Appreciates Stable Blood Pressure.American journal of hypertension · 2018Article
- Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Article
- APOL1 Gene Kidney Risk Variants and Cardiovascular Disease: Getting to the Heart of the Matter.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Review
- BP Control and Long-Term Risk of ESRD and Mortality.Journal of the American Society of Nephrology : JASN · 2017Article
- Strict blood pressure control associates with decreased mortality risk by APOL1 genotype.Kidney international · 2017Article
- Current State and Future Trends to Optimize the Care of African Americans with End-Stage Renal Disease.American journal of nephrology · 2017Review
- Observational
- APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease.Kidney international · 2016Article
- Risk Factors for Rapid Kidney Function Decline Among African Americans: The Jackson Heart Study (JHS).American journal of kidney diseases : the official journal of the National Kidney Foundation · 2016Article
- Hypertension-attributed nephropathy: what's in a name?Nature reviews. Nephrology · 2016Review
- Cause-Specific Deaths in Non-Dialysis-Dependent CKD.Journal of the American Society of Nephrology : JASN · 2015Article
- Estimating time to ESRD using kidney failure risk equations: results from the African American Study of Kidney Disease and Hypertension (AASK).American journal of kidney diseases : the official journal of the National Kidney Foundation · 2015Observational
Corrections and comments
- Commented on by
Authors and funding
8 authors at 7 institutions in 1 country.
Funding
Abstract
In several studies, patients with CKD seemed to be at greater risk for dying from cardiovascular disease (CVD) than reaching ESRD. The purpose of this study was to compare incident ESRD rates with rates of total mortality, CVD death, and a CVD composite (CVD mortality and CVD hospitalization) among participants who had hypertensive nephrosclerosis and were enrolled in the African American Study of Kidney Disease and Hypertension (AASK). The study period included the AASK trial phase (1996 through 2001) and a subsequent cohort phase (2002 through 2007). The AASK enrolled 1094 participants. Of the 764 participants who completed the trial phase without an event, 691 (90%) enrolled in the cohort phase. During 11 years of follow-up, there were 59 CVD-related deaths and 118 non-CVD-related deaths. The rate of ESRD (3.9/100 patient-years) was significantly higher than the rates of total mortality (2.2/100 patient-years), CVD mortality (0.8/100 patient-years), and the CVD composite (3.2/100 patient-years). The incidence rate ratio of ESRD to CVD mortality was 5.0. The rate of ESRD consistently exceeded the various mortality rates across most of the subgroups defined by age, gender, income, education, previous CVD, baseline urine protein excretion, and baseline estimated GFR. In conclusion, AASK participants were more likely to reach ESRD than to die.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.